Page last updated: 2024-08-23

idarubicin and Leukemia, Megakaryocytic

idarubicin has been researched along with Leukemia, Megakaryocytic in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bacher, U; Bokemeyer, C; Fiedler, W; Haalck, T; Janjetovic, S; Janning, M	1
Creutzig, U; Diekamp, S; Dworzak, M; Fleischhack, G; Harbott, J; Langebrake, C; Ludwig, WD; Reinhardt, D; Ritter, J; Schrauder, A; Stary, J; Zimmermann, M	1
Creutzig, U; Diekamp, S; Dworzak, M; Reinhardt, D; Stary, J; Zimmermann, M	1

Trials

1 trial(s) available for idarubicin and Leukemia, Megakaryocytic

Article	Year
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia, 2005, Volume: 19, Issue:8 Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome	2005

Article

Year

AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.

Leukemia, 2005, Volume: 19, Issue:8

Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Survival Rate; Treatment Outcome

2005

Other Studies

2 other study(ies) available for idarubicin and Leukemia, Megakaryocytic

Article	Year
Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects. Acta haematologica, 2013, Volume: 129, Issue:2 Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum	2013
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment. Leukemia, 2005, Volume: 19, Issue:8 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Male; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome	2005

Article

Year

Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.

Acta haematologica, 2013, Volume: 129, Issue:2

Topics: Adult; Aneuploidy; Cytarabine; Daunorubicin; DNA Repair; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Recurrence; Remission Induction; Transplantation, Homologous; Vidarabine; Xeroderma Pigmentosum

2013

Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.

Leukemia, 2005, Volume: 19, Issue:8

Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infant; Leukemia, Megakaryoblastic, Acute; Male; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome

2005